Search results for "EDEMA"

showing 10 items of 625 documents

Postoperative education concerning the use of the upper limb, and exercise and treatment of the upper limb: cross-sectional survey of 105 breast canc…

2003

In this retrospective survey we investigated the recall of breast cancer patients (n=105) 6 months after the operation concerning postoperative instructions on exercises for shoulder mobility, and instructions for oedema prevention and treatment, upper limb strength training and the use of the upper limb in daily activities. Patients also described the content in their own words and ranked the instructors who had mostly given this education. Operation type and length of hospital stay did not have any effect on the education recalled, but the age of the respondent had some effect (r=−0.23, p<0.05). The Wilcoxon signed ranks test showed that the most commonly reported item was instructions on…

medicine.medical_specialtyActivities of daily livingCross-sectional studyStrength trainingmedicine.medical_treatmentBreast NeoplasmsPhysiotherapy assistant03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationBreast cancerPatient Education as TopicMedicineEdemaHumansExerciseFinlandRehabilitation030504 nursingbusiness.industrymedicine.disease3. Good healthmedicine.anatomical_structureCross-Sectional StudiesOncology030220 oncology & carcinogenesisRespondentPhysical therapyArmUpper limbFemale0305 other medical sciencebusinessSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
researchProduct

An update on hypertensive emergencies and urgencies

2015

Severe acute arterial hypertension is usually defined as 'hypertensive crisis', although 'hypertensive emergencies' or 'hypertensive urgencies', as suggested by the Joint National Committee and the European Society of Hypertension, have completely different diagnostic and therapeutic approaches. The prevalence and demographics of hypertensive emergencies and urgencies have changed over the last four decades, but hypertensive emergencies and urgencies are still associated with significant morbidity and mortality. Different scientific societies have repeatedly produced up-to-date guidelines; however, the treatment of hypertensive emergencies and urgencies is still inappropriate, with potentia…

medicine.medical_specialtyAcute coronary syndromehypertensionDemographicshypertensive emergencieacute coronary syndromehypertensive urgencieAneurysm Dissectingacute coronary syndrome acute pulmonary oedema hypertension hypertensive urgencies hypertensive emergencies strokeTerminology as TopicHumansMedicineHypertension diagnosisDisease management (health)Intensive care medicineStrokeAcute pulmonary oedemaEmergencieHeart Failurebusiness.industryhypertensive urgenciesDisease Managementhypertensive emergenciesGeneral MedicineAneurysm dissectingacute pulmonary oedemaacute coronary syndrome; acute pulmonary oedema; hypertension; hypertensive emergencies; hypertensive urgencies; stroke; Cardiology and Cardiovascular MedicineHypertensive crisismedicine.diseaseAortic AneurysmStrokeAortic DissectionAcute Diseaseacute coronary syndrome; acute pulmonary oedema; hypertensionEmergenciesCardiology and Cardiovascular MedicinebusinessHuman
researchProduct

Hereditary Angioedema: Increased Number of Attacks after Frequent Treatments with C1 Inhibitor Concentrate

2009

OBJECTIVE: C1 inhibitor concentrate is regarded as effective and safe in treating acute attacks of hereditary angioedema caused by C1 inhibitor deficiency. This study investigated the course of disease in 3 women treated frequently with C1 inhibitor concentrate. METHODS: Three women are described who received C1 inhibitor concentrate for the treatment of acute attacks of hereditary angioedema and experienced an increase in the frequency of attacks during that treatment period. In a control group of 24 patients aged more than 60 years with hereditary angioedema, the natural course of disease was determined. RESULTS: The 3 women (ages 50, 69, and 72 years) had received C1 inhibitor concentrat…

medicine.medical_specialtyAllergyPediatricsC1 inhibitor deficiencyDiseaseC1-inhibitorRecurrenceImmunopathologyHumansMedicineAgedNatural coursebiologybusiness.industryAngioedemas HereditaryGeneral MedicineMiddle Agedmedicine.diseaseTreatment periodSurgeryAcute DiseaseHereditary angioedemabiology.proteinFemalebusinessComplement C1 Inhibitor ProteinThe American Journal of Medicine
researchProduct

A C1-inhibitor rare mutation: Early diagnosis of hereditary angioedema in a paediatric patient

2013

Hereditary angioedema secondary to C1-inhibitor deficiency is a rare autosomal dominant disorder characterized by a deficiency of C1 esterase inhibitor.An eight-year-old girl showed periorbital painless swelling, diagnosed as ethmoiditis. A craniofacial scan did not evidence a paranasal sinus involvement, C1INH levels were undetectable, with low C4 levels: 7.6 mg/dl and C1INH: <8.46 mg/dl. The genetic study identified a rare mutation of the C1INH gene. This clinical report is of relieve because paediatric cases described in literature are rare, did not presented a positive family history, and received a diagnosis after many attacks. Furthermore our girl received a prompt diagnosis of HAE at…

medicine.medical_specialtyAngioedemabiologybusiness.industrymedicine.diseaseDermatologySurgeryC1-inhibitormedicine.anatomical_structureMutation (genetic algorithm)Hereditary angioedemamedicinebiology.proteinmedicine.symptomCraniofacialFamily historybusinessSinus (anatomy)Paediatric patientsOpen Journal of Pediatrics
researchProduct

Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema

2010

BACKGROUND Hereditary angioedema is characterized by recurrent attacks of angioedema of the skin, larynx, and gastrointestinal tract. Bradykinin is the key mediator of symptoms. Icatibant is a selective bradykinin B2 receptor antagonist. METHODS In two double-blind, randomized, multicenter trials, we evaluated the effect of icatibant in patients with hereditary angioedema presenting with cutaneous or abdominal attacks. In the For Angioedema Subcutaneous Treatment (FAST) 1 trial, patients received either icatibant or placebo; in FAST-2, patients received either icatibant or oral tranexamic acid, at a dose of 3 g daily for 2 days. Icatibant was given once, subcutaneously, at a dose of 30 mg. …

medicine.medical_specialtyAngioedemabusiness.industryGeneral MedicinePlacebomedicine.diseaseSurgerylaw.inventionEcallantidechemistry.chemical_compoundRandomized controlled trialchemistrylawIcatibantAnesthesiaHereditary angioedemamedicinemedicine.symptomBradykinin receptorbusinessTranexamic acidmedicine.drugNew England Journal of Medicine
researchProduct

Hereditary angioedema type III, angioedema associated with angiotensin II receptor antagonists, and female sex

2004

medicine.medical_specialtyAngiotensin receptorAngioedemaC1 inhibitor deficiencybusiness.industryFemale sexGeneral Medicinemedicine.diseaseEndocrinologyInternal medicineHereditary angioedemamedicineHereditary Angioedema Type IIImedicine.symptombusinessThe American Journal of Medicine
researchProduct

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Dis…

2020

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, is being defined as the worst pandemic disease of modern times. Several professional health organizations have published position papers stating that there is no evidence to change the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in the management of elevated blood pressure in the context of avoiding or treating COVID-19 infection. In this article, we review the evidence on the relationship between the renin-angiotensin-aldosterone system and COVID-19 infection. In agreement with current guidelines, patients with hypertension should continue taki…

medicine.medical_specialtyAngiotensin-Converting Enzyme030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusmedicinecardiovascular diseases030212 general & internal medicineAdverse effectbiologyAngioedemabusiness.industryCOVID-19Angiotensin-converting enzymeGeneral Medicinemedicine.diseaseCoronavirusBlood pressureAngiotensin-Converting Enzyme Coronavirus COVID-19Heart failureAngiotensin-converting enzyme 2biology.proteinmedicine.symptombusinessKidney diseaseMayo Clinic Proceedings
researchProduct

Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs

2002

Background Adverse reactions to non-steroidal anti-inflammatory drugs (NSAID)s are frequent, and the need to identify a safe alternative drug is a common problem in clinical practice. Objective To assess the tolerability of rofecoxib, a drug that specifically inhibits COX-2, in a group of NSAID-sensitive patients. Methods One-hundred and four subjects (29 males and 75 females, mean age 35.6 ± 14.1) were enrolled. All subjects had experienced one or more episode characterized by cutaneous symptoms (erythema, and/or urticaria angioedema) following the assumption of NSAIDs; 92 subjects experienced reactions to only one NSAID (single intolerance: SI) and 12 subjects had reactions to multiple NS…

medicine.medical_specialtyAspirinAngioedemaErythemabusiness.industryImmunologyAngioneurotic oedemaPlacebolaw.inventionTolerabilityRandomized controlled triallawInternal medicineAnesthesiamedicineImmunology and Allergymedicine.symptomskin and connective tissue diseasesbusinessRofecoxibmedicine.drugClinical &amp; Experimental Allergy
researchProduct

Indirekte MR-Arthrographie zur Verlaufskontrolle nach autologer osteochondraler Transplantation

2003

Purpose: To evaluate the spectrum of findings in indirect MR-arthrography following autologous osteochondral transplantation. Patients and Methods: 10 patients with autogenous osteochondral homografts underwent indirect MR-arthrography at three, 6 and 12 months postoperatively. The MR protocol at 1.5 T comprised unenhanced imagings with PD- and T 2 -weighted TSE-sequences with and without fat-suppression as well as T 1 -weighted fat-suppressed SE-sequences before and after iv. contrast ad ministration and after active joint exercise. Image analysis was done by two radiologists in conference and comprised the evaluation of signal intensity (Sl) and integrity of the osseous plug and the carti…

medicine.medical_specialtyBone diseaseHyaline cartilagebusiness.industryCartilageFollow up studiesJoint effusionBone marrow edemamedicine.diseaseSurgerymedicine.anatomical_structuremedicineRadiology Nuclear Medicine and imagingmedicine.symptombusinessPathologicalFixation (histology)RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
researchProduct

Hereditary angioedema: an update on causes, manifestations and treatment.

2019

Hereditary angioedema is a rare genetic disorder caused by deficiency of C1 esterase inhibitor (C1-INH) and characterized by recurrent episodes of severe swelling that affect the limbs, face, intestinal tract and airway. Since laryngeal oedema can be life-threatening as a result of asphyxiation, correct diagnosis and management of hereditary angioedema is vital. Hereditary angioedema attacks are mediated by bradykinin, the production of which is regulated by C1-INH. Hereditary angioedema therapy relies on treatment of acute attacks, and short- and long-term prophylaxis. Acute treatment options include C1-INH concentrate, icatibant and ecallantide. Self-administration of treatment is recomm…

medicine.medical_specialtyBradykinin03 medical and health sciences0302 clinical medicineimmune system diseasesmedicineHumanscardiovascular diseases030212 general & internal medicineskin and connective tissue diseasesHereditary Angioedema Types I and IIbusiness.industryGenetic disorderfood and beveragesGeneral Medicinemedicine.diseaseDermatologyC1 esterase030228 respiratory systemHereditary angioedemaFactor XIIDisease ProgressionQuality of LifeKallikreinsbusinessPeptidesComplement C1 Inhibitor ProteinBritish journal of hospital medicine (London, England : 2005)
researchProduct